Objective: To examine the relation between low-contrast letter acuity, an emerging visual outcome for multiple sclerosis (MS) clinical trials, and brain MRI abnormalities in an MS cohort.
Visual dysfunction is a common cause of disability in multiple sclerosis (MS) 1 and is best identified clinically using low-contrast letter acuity. 2, 3 Low-contrast acuity scores readily distinguish patients with MS from disease-free controls, and differ among MS disease subtypes. 4, 5 A candidate component for the MS Functional Composite (MSFC), lowcontrast acuity demonstrated treatment effects in two recent trials of natalizumab for relapsing MS.
One of the most important aspects of validating clinical outcomes is their correlation with structural markers of disease. 6, 7 Whereas low-contrast acuity scores correlate well with retinal nerve fiber layer (RNFL) thickness by optical coherence tomography (OCT), 8 the contribution of brain abnormalities beyond the pregeniculate pathways has not been established. To the extent that low-contrast acuity is now being incorporated into MS trials, assessments of how this clinical test reflects MRI measures are important.
The visual system represents a useful model for identifying MRI correlates to clinical impairment in MS, offering an opportunity to evaluate how a specific function reflects MRI findings for whole brain and within regions of interest. The purpose of this study was to examine the relation of low-contrast letter acuity scores to brain MRI abnormalities in MS, with the hypothesis that greater T2 lesion burden will be associated with lower (worse) scores for low-contrast acuity. We also sought to determine whether regional abnormalities within optic tracts, optic radiations, and Area 17 would be more powerful predictors of visual function than whole brain measures, and to examine the potential contribution of postgeniculate afferent pathway structures to visual dysfunction.
METHODS Patients and neurologic evaluation.
Forty-five patients enrolled in a prospective study of visual outcomes in MS 4 underwent brain MRI for purposes of these cross-sectional analyses. Subjects represented a subset of patients willing to undergo imaging for research purposes; patients were not selected specifically for imaging based on clinical features or extent of symptoms. The diagnosis of MS was confirmed by clinical criteria. 9 Neurologic status was determined using the Expanded Disability Status Scale (EDSS) and the MSFC (includes a timed 25-ft walk, ninehole peg test, and paced auditory serial addition test [PASAT]). 10 Study protocols were approved by the University of Pennsylvania institutional review board, and each subject provided written informed consent. The study was conducted in accordance with Health Insurance Portability and Accountability Act (HIPAA) guidelines.
MRI acquisition and image analysis. Fast spin echo
T2-weighted and proton density-weighted images of the brain were acquired for all subjects on 1.5-T scanners (GE and Siemens) with a head coil using the following: repetition time ϭ 2,500 msec, echo time ϭ 30/90 msec, 512 ϫ 512 ϫ 44 or 256 ϫ 256 ϫ 44 resolution, and voxel sizes of 0.43 ϫ 0.43 ϫ 3 mm 3 or 0.86 ϫ 0.86 ϫ 3 mm 3 . All image data were transmitted to the image analysis center (Medical Image Processing Group) electronically via a Digital Imaging and Communications in Medicine (DICOM) interface adhering to HIPAA regulations and converted to an n-dimensional generalization of the DICOM format of the 3DVIEWNIX software system. 11 Image processing and analysis were performed by 3DVIEWNIX-BRN, a version of 3DVIEWNIX specially designed for the analysis of magnetic resonance images of the brain in neurologic applications. For each patient, the methodology for defining whole brain MRI morphologic measures consisted of the following steps: 1) correction of the acquired patient images for background intensity variation arising from magnetic field nonuniformities 12 ; 2) processing of the resulting images to standardize their intensities 13 ; 3) segmentation of the standardized images 14 to obtain gray matter, white matter, and CSF regions (brain parenchymal [BP] region was defined as the union of gray and white matter regions); and 4) computation of the volumes of BP, gray matter, white matter, and lesions for the whole brain normalized by the intracranial volume, which is the volume of the union of BP and CSF (ventricular and sulcal CSF) regions. Brain parenchymal fraction (BPF) was thus calculated as BP/(BP ϩ CSF).
Several similar steps were used for determining the regional MRI morphologic measures. First, posterior visual pathway regions of interest (ROIs), including Brodmann Area 17, were manually defined according to standard reference atlases 15, 16 on one template brain image represented in the normalized space using MRICro software. 16 Second, these ROIs subsequently mapped automatically to each patient image by using a deformable registration process via the software system SPM2. 17 For each of BP, gray matter, white matter, and lesion regions, the subset that falls within each of the mapped anatomic functional regions was determined from the segmentation results obtained in Step 3 above. Finally, the volumes of these tissue regions within each of the functional regions were computed as in Step 4 above.
Visual function testing.
Visual function was assessed using high-and low-contrast letter acuity testing. Highcontrast visual acuity (similar to Snellen acuity) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts at 3.2 m (Lighthouse Low Vision Products, Long Island City, NY). 18 Low-contrast letter acuity was measured using low-contrast Sloan letter charts (Sloan charts, 1.25% and 2.5% contrast levels at 2 m; Precision Vision, LaSalle, IL). 3, 4 Sloan charts have a standardized format based on that of the ETDRS visual acuity charts (5 letters/line). 3, 4 Each Sloan chart corresponds to a different contrast level, and charts are scored based on the number of letters identified correctly. This format may allow Sloan charts to capture losses of contrast at small letter sizes that have been reported in MS and other neurologic disorders. 19 All vision testing was performed binocularly (with both eyes open). Binocular testing has been used successfully in recent MS trials and methodologic studies [2] [3] [4] [5] 20 and has been recently recommended as a primary outcome for ophthalmologic clinical trials that assess visual function. Charts were scored letter-by-letter, with each line of vision corresponding to 5 letters.
Statistical analyses.
Linear regression models were used to examine the relation between MRI measures and visual functions scores, accounting simultaneously for age and disease duration. History of one or more episodes of acute optic neuritis, assessed by self-report and physician report, was included in some regression models to explore the effect of this variable on the relation of vision to MRI. Pearson linear correlation coefficients were also calculated to determine the magnitude of this relation in terms of univariate analyses.
Type I error for significance was set at p Ͻ 0.05. Stata 8.0 software (StataCorp, College Station, TX) was used for all analyses and calculations.
RESULTS Characteristics of the cohort. Demographic and clinical data are summarized in table 1. Characteristics of our patient cohort were similar to the US MS population with respect to sex and age, 21 and most patients had relapsing-remitting MS (95%). Relatively broad ranges of overall neurologic impairment and disease duration were represented. The mean MRI T2 lesion volume was 18.5 Ϯ 14.9 mm 3 , and the mean BPF was 88.3 Ϯ 3.7%, consistent with values from published cohorts of MS patients.
22,23
Relation of low-contrast letter acuity to global MRI measures. Accounting for age and disease duration, patients with lower (worse) low-contrast letter acuity and high-contrast visual acuity (VA) scores had greater T2 lesion volumes in whole brain (2.5% contrast level: adjusted R 2 0.26, p ϭ 0.004; 1.25% contrast level: adjusted R 2 0.25, p ϭ 0.002; VA: adjusted R 2 0.17, p ϭ 0.04, linear regression models, table 2). Adjusted R 2 values represent the percentage of the total variance in MRI measure (such as T2 lesion volume) that can be explained by the linear regression model covariates of visual function score, age, and disease duration, adjusted for degrees of freedom. On average, a 1-line (5-letter) worsening of low-contrast letter acuity score corresponded to a 3-mm 3 increase in T2 lesion volume within whole brain (this is represented by the ␤ coefficients for T2 lesion volume in table 2), whereas a 1-line worsening in high-contrast visual acuity corresponded to a 5.5-mm 3 increase in lesion volume. Pearson linear correlations between T2 lesion volume and low-contrast letter acuity scores were modest in magnitude, indicating worse vision scores in the setting of higher lesion burden (2.5% contrast level: r ϭ Ϫ0.44, p ϭ 0.002; 1.25% contrast level: r ϭ Ϫ0.43, p ϭ 0.003; VA: r ϭ Ϫ0.33, p ϭ 0.02, figure 1 ). These correlations were greater than those between T2 lesion volume and MSFC z-scores (r ϭ Ϫ0.16, p ϭ 0.28) and EDSS scores (r ϭ 0.07, p ϭ 0.63) in this cohort. Unlike linear regression models, these simple correlations do not account for factors such as age and disease duration, which may affect the relation between vision and MRI measures.
The ratio of T2 lesion volume to total white matter volume, reflective of the proportion of "abnormal" white matter, was also higher among patients with worse visual function (adjusted R 2 0.35 to 0.36, p ϭ 0.001 for low-contrast letter acuity at 2.5% and 1.25% contrast levels, table 2). Accounting for history of acute optic neuritis did not alter the relation between visual function and T2 lesion volume (or lesion volume to total white matter volume ratio) for whole brain (adjusted R 2 and p values in parentheses, table 2). Reductions in BPF were less well correlated with worsening in visual function (high-contrast visual acuity: r ϭ 0.27, p ϭ 0.08; low-contrast acuity: r ϭ 0.12 to 0.17, p ϭ 0.28 to 0.44, figure 1 ). This pattern was also seen in analyses accounting for age and disease duration (table 2) . Consistent with previous studies, correlations between BPF and EDSS scores were not significant (r ϭ 0.15, p ϭ 0.34). Lower (worse) MSFC z-scores and were observed among patients with lower BPF, with a trend toward significance (r ϭ 0.24, p ϭ 0.10; adjusted R 2 0.05, p ϭ 0.05, accounting for age and disease duration).
Low-contrast letter acuity and visual pathway regions of interest.We hypothesized that correlations between visual dysfunction and MRI abnormalities may depend on structural changes within regions of the afferent visual system. To address this hypothesis, a method of mapping brain regions was used. Posterior visual pathway ROIs, including Brodmann Area 17, were outlined on a standardized brain MRI image set (figure 2) . These regions were then mapped to each subsequent brain MRI obtained from study participants using deformable registration. 17 For these analyses, the cerebellum served as an anatomic and functional internal control.
Lesion volumes within Area 17 white matter (2.5% contrast level: adjusted R 2 0.30, p Ͻ 0.001; 1.25% contrast level: adjusted R 2 0.12, p ϭ 0.02) and the optic radiations (2.5% contrast level: adjusted R 2 0.24, p ϭ 0.001; 1.25% contrast level: adjusted R 2 0.09, p ϭ 0.02) were greater among patients with lower (worse) scores for lowcontrast letter acuity, accounting for age and disease duration (table 3) . Reductions in highcontrast visual acuity were also associated with greater lesion volumes in Area 17 (adjusted R 2 0.13, p ϭ 0.01) and the optic radiations (adjusted R 2 0.14, p ϭ 0.007, table 3). Similar to analyses for whole brain, accounting for history of acute optic neuritis did not affect the relation of visual function to lesion volumes in postgeniculate white matter structures. Associations of lowcontrast acuity scores and optic tract lesion volumes were not significant. Magnitudes of linear correlations followed a pattern similar to that observed for regression models in table 3 (2.5% contrast: Area 17 lesion volume: r ϭ Ϫ0.53, p ϭ 0.0003; optic radiation lesion volume: r ϭ Ϫ0.50, p ϭ 0.001; optic tract lesion volume: r ϭ Ϫ0.01, p ϭ 0.94). Correlations at 1.25% contrast and for high-contrast visual acuity were significant for Area 17 and optic tracts, but were somewhat lower than those observed for the 2.5% contrast level. Correlations of high-and low-contrast acuity scores with cerebellar T2 lesion volume (structure included as a control) were small, particularly for at low-contrast levels (1.25%: r ϭ 0.08, p ϭ 0.56; 2.5%: r ϭ 0.10, p ϭ 0.48; VA: r ϭ 0.21, p ϭ 0.10).
Magnetization transfer ratio histogram analyses. In patients with MS, intrinsic tissue damage within the brain, separate from volumetric changes, can be reflected by magnetization transfer ratio (MTR) histogram characteristics. 24 Whereas positions of the 25th, 50th, and 75th percentiles showed no significant correlations with visual Absolute values of linear correlations between visual function scores and global (whole brain) MRI measures LSV ϭ T2 lesion volume; LSV/NLSV ϭ ratio of lesion volume to total white matter volume; BPF ϭ brain parenchymal fraction. Lines are drawn between data points for illustrative purposes.
dysfunction, greater MTR histogram peak height values for whole brain white matter, which represent remaining viable axonal substrate, 25 were associated with higher (better) scores for lowcontrast letter acuity (2.5% contrast level: total white matter: adjusted R 2 0.37, p ϭ 0.03; normalappearing [nonlesional] white matter: adjusted R 2 0.18, p ϭ 0.04). Area 17 total white matter and normal-appearing white matter also demonstrated higher MTR histogram peak heights among patients with better scores for lowcontrast acuity (2.5% contrast level: total white matter: adjusted R 2 0.49, p ϭ 0.02; normalappearing white matter: adjusted R 2 0.22, p ϭ 0.03; 1.25% contrast level: total white matter: adjusted R 2 0.44, p ϭ 0.04; normal-appearing white matter: adjusted R 2 0.23, p ϭ 0.02). Interestingly, the correlation between MTR histogram peak height for cerebellum (intended as a control) and low-contrast letter acuity (1.25% contrast level) were similar to BPF and were also not significant for normal-appearing white matter (adjusted R 2 0.20, p ϭ 0.12), whereas the relation to T2 lesion volumes in cerebellum was not significant for low-contrast letter acuity.
DISCUSSION Results of this investigation demonstrate that scores for low-contrast letter acuity, a promising visual outcome for MS clinical trials, correlate well with T2 lesion burden in whole brain and within postgeniculate visual pathway structures of Area 17 (occipital) white matter and optic radiations. Patients with greater disease burden have lower (worse) scores for lowcontrast letter acuity, whereas deficits in highcontrast visual acuity are more reflective of loss of brain tissue (BPF). These findings support a role for low-contrast acuity testing in future MS trials and suggest that disease in the postgeniculate white matter is a contributor to visual dysfunction in MS.
Magnitudes of correlations between low-contrast letter acuity scores and T2 lesion volume in this study were similar to or greater than those of previous studies of the MSFC and its components. 7, 26 Also consistent with previous studies was our observation that EDSS scores do not correlate significantly with morphometric MRI measures. 7, 27 In previous studies, crosssectional correlations between measures of disability and conventional brain MRI abnormalities in MS have been modest. 7, [27] [28] [29] Among potential reasons for this is the relative shortage of studies analyzing specific brain regions. Examples of the relevance for regional analysis include a large series of patients. 30 This study showed a tendency for lesions to accumulate within specific regions, with significant correlations between ambulation and lesion burden in the left internal capsule. Studies of diffusion tensor tractography have shown that abnormalities within the corpus callosum correlate with cognition. 31 Conversely, pyramidal tract damage, represented by spinal cord pathway atrophy, is moderately related to neurologic disability as measured by the EDSS. 32 A recent longitudinal study 33 demonstrated that T2 lesion volumes whole brain were related to future clinical disability as measured by the MSFC, and that, among several MRI measures, T2 lesion burden was the strongest predictor of future neurologic impairment, cognitive deficits, and loss of brain tissue.
The optic nerves and other pregeniculate visual pathway structures are frequent sites for demyelination and axonal loss that has been confirmed by pathologic studies, by MRI, and by measurements of RNFL thickness. 8 Losses of RNFL as measured by OCT correlate significantly with reductions in low-contrast letter acuity. 8 Other investigations have provided evidence for deficits in contrast discrimination among patients with cerebral lesions and have suggested that perception of low-contrast targets, particularly those of smaller size (approximately 20/25 Snellen acuity equivalent), involve processing in the postgeniculate visual pathways. [34] [35] [36] Low-contrast Sloan letter charts measure patients' ability to identify low-contrast letters of progressively smaller size on a white background, and potentially capture losses of contrast perception at small letter sizes. Investigations are under way to examine MRI abnormalities in the postgeniculate visual pathway and their relation to RNFL thickness, perhaps further defining the contributions of each to losses of low-and high-contrast acuity in patients with MS. Binocular testing of low-contrast letter acuity has been used thus far in MS clinical trials that have incorporated this measure as a tertiary outcome. 20 Therefore, it is this type of measurement of visual function whose correlations with MRI measures are of interest. For purposes of MS clinical trials, binocular testing has several advantages. First, testing using both eyes together minimizes patient fatigue, which may be an important factor when patients must undergo multiple assessments as part of a clinical trial protocol. Binocular testing also best provides an assessment of visual function as is present for daily activities with both eyes open. This is analogous to the fact that the MSFC incorporates a timed ambulation test rather than tests of individual leg strength or coordination. Binocular testing of acuity has also gained increasing acceptance and recognition as a primary outcome in ophthalmologic clinical trials that assess visual function. 20 Recent studies using OCT have shown strong correlations between low-contrast acuity scores, measured for each eye separately, and RNFL thickness, suggesting that this visual function test captures tissue loss within the anterior (pregeniculate) visual pathways. 8 In such studies involving OCT, use of binocular vision testing could underestimate the degree of axonal loss (due to binocular summation between the two eyes). However, binocular low-contrast acuity measurements may represent a better predictor of postgeniculate visual pathway pathology, including both afferent and efferent aspects of visual function.
Previous studies of the MSFC have also examined the potential role for T1 hypointense lesion load; this was not examined in our investigation but may represent an important marker for axonal and neuronal loss. Whereas a follow-up study of patients enrolled in a Phase III trial of interferon ␤-1a for relapsing-remitting MS found higher correlations with BPF for low-contrast acuity than for high-contrast visual acuity, 37 correlations with low-contrast acuity were similar to those for high-contrast acuity in the present cohort. Patients in the follow-up study (n ϭ 137) were of similar age to our cohort at the time of analyses but had greater disease duration (mean 13.8 years vs 6.9 years), higher EDSS scores (4.1 vs 2.5), and lower BPF (0.80 vs 0.88). These differences between our cohort and the larger follow-up study suggest a need for additional investigations of how visual function in MS may reflect loss of axons and tissue in whole brain as well as in the pregeniculate afferent visual pathways (RNFL thickness by OCT).
Several previous reports have highlighted the need for regional MRI analyses in studies of MS. 27, 30 The visual system in MS provides a unique opportunity to examine the relation between a specific function and the corresponding anatomic structures. Newer methodologies, including magnetization transfer imaging, 38 diffusion tensor imaging, 39 and intensity-based measures that use conventional T2 or protondensity MRI 40 may increase the sensitivity for detection of abnormalities. For example, increased tesla strength alone yields a greater capacity to identify T2 lesion burden. 41 Our investigation did not demonstrate significant correlations with visual function for optic tracts, even when history of acute optic neuritis was not accounted for in the regression models. One potential factor may be the relatively small size of these white matter structures (arrows in figure 2D ) compared with Area 17 and optic radiations. Size is likely important to the detection of T2 lesions.
The relation between better scores for lowcontrast letter acuity and greater white matter MTR histogram peak heights (reflecting residual viable neural tissue) 25 was also an important finding. Whereas correlations with low-contrast acuity were significant for whole brain total and nonlesional white matter, results for Area 17 were of similar magnitude to whole brain values. These data complement those for T2 lesion volumes, supporting a potential influence of postgeniculate white matter disease on vision in MS.
Among measures examined in our crosssectional study, T2 lesion volume was the strongest correlate of visual function. A recent longitudinal study emphasized the importance of lesion burden in defining future clinical and cognitive impairment (MSFC and PASAT3 scores) as well as in predicting loss of brain tissue (BPF) and compromise of brain tissue integrity (MTR in normal-appearing brain tissue). 33 Ongoing studies are examining how worsening of low-contrast letter acuity over time in MS may be associated not only with reductions in RNFL thickness as a marker for pregeniculate visual pathway axonal loss, but also with accumulation of whole brain and regional T2 lesion burden.
